ライフサイエンスコーパス: intraepithelial neoplasia

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 tal intraepithelial neoplasias (eg, cervical intraepithelial neoplasia).

2 ulation, leading to development of prostatic intraepithelial neoplasia.

3 arly as at the stage of high-grade prostatic intraepithelial neoplasia.

4 ve to surgery in female patients with vulval intraepithelial neoplasia.

5 results showed that 4 eyes had conjunctival intraepithelial neoplasia.

6 oliferation, hyperplasia, and early prostate intraepithelial neoplasia.

7 acilitates the onset of high-grade prostatic intraepithelial neoplasia.

8 e of palpable tumor and high-grade prostatic intraepithelial neoplasia.

9 e without affecting hyperplasia or prostatic intraepithelial neoplasia.

10 yperplasia, or dysplastic lesions/pancreatic intraepithelial neoplasia.

11 fficient to induce hyperplasia and prostatic intraepithelial neoplasia.

12 etaplasia, dysplasia, and ultimately gastric intraepithelial neoplasias.

13 papillary mucinous neoplasms and in multiple intraepithelial neoplasias.

14 pancreatic ducts, referred to as pancreatic intraepithelial neoplasias.

15 mice, but did not alter growth of pancreatic intraepithelial neoplasias.

16 and tolerable for treating usual-type vulvar intraepithelial neoplasia?

17 n of oncogenic KRAS, premalignant pancreatic intraepithelial neoplasia 1 (PanIN1) lesions rarely beco

18 ntial reduction of ADM as well as pancreatic intraepithelial neoplasia-1 (PanIN-1), PanIN-2, and PanI

19 Its expression is lost at the pancreatic intraepithelial neoplasia 1b (PanIN1b)/PanIN2 stage of p

20 e 70% of cervical cancer and 50% of cervical intraepithelial neoplasia 2/3 and adenocarcinoma in situ

21 Development of cervical intraepithelial neoplasia 2/3 was rare in women with red

22 ening algorithm found more disease (cervical intraepithelial neoplasia 3 or worse [CIN3+]) and also f

23 I, 1.67 to 3.31); grade 2 or higher cervical intraepithelial neoplasia, 6.9% vs. 3.4% (hazard ratio,

24 (2 benign papillomas, 2 grade 2 conjunctival intraepithelial neoplasias, 7 in situ squamous carcinoma

25 ring developed intestinal lesions, including intraepithelial neoplasia, adenomas, and adenocarcinomas

26 s to surgery for female patients with vulval intraepithelial neoplasia after exclusion of occult inva

27 High-grade anal intraepithelial neoplasia (AIN) is present in many human

28 ients, including 11 low-grade, 14 high-grade intraepithelial neoplasia and 12 invasive carcinoma in 3

29 lly classified as benign prostate, prostatic intraepithelial neoplasia and adenocarcinoma, can be eva

30 normal mammary epithelium, developed ductal intraepithelial neoplasia and DCIS, and progressed to in

31 (Fl/Fl)) failed to progress beyond prostatic intraepithelial neoplasia and did not harbor genomic CNA

32 es local conservative treatment for cervical intraepithelial neoplasia and early invasive cervical ca

33 becomes highly expressed in human prostatic intraepithelial neoplasia and in PCa, and that the funct

34 diminished SC chemoattraction to pancreatic intraepithelial neoplasia and increased abdominal hypers

35 enic mice presented with high-grade prostate intraepithelial neoplasia and increased nuclear cyclin D

36 levels of H3K27me3 are reduced in prostatic intraepithelial neoplasia and invasive adenocarcinoma le

37 low but increases significantly in cervical intraepithelial neoplasia and invasive squamous cervical

38 with Skp2 expression in high-grade prostatic intraepithelial neoplasia and PCa.

39 reased significantly in high-grade prostatic intraepithelial neoplasia and PCa.

40 ls in culture and for Kras-driven pancreatic intraepithelial neoplasia and PDAC formation in vivo.

41 ith c-myc overexpression to induce prostatic intraepithelial neoplasia and prostate cancer.

42 that Olfm4-knockout mice developed prostatic intraepithelial neoplasia and prostatic adenocarcinoma.

43 the expression of AnxA2 is lost in prostate intraepithelial neoplasia and reappears in the high-grad

44 l, leading to early onset of mouse prostatic intraepithelial neoplasia and the progression of prostat

45 , safe, and feasible for treatment of vulval intraepithelial neoplasia and warrant further investigat

46 The incidence of the prostatic intraepithelial neoplasia and well-differentiated (WD) c

47 ho received RFA for BE containing high-grade intraepithelial neoplasia and/or early-stage cancer for

48 rrett's esophagus (BE) containing high-grade intraepithelial neoplasia and/or early-stage cancer.

49 promote progression of high-grade prostatic intraepithelial neoplasia and/or prostate cancers that e

50 as HPV DNA is detected in up to 90% of anal intraepithelial neoplasias and anal cancers.

51 ns, but progression to high-grade pancreatic intraepithelial neoplasias and PDAC is blocked.

52 and RAC1 were increased in human pancreatic intraepithelial neoplasias and PDAs compared with health

53 rom the transgenic mice regenerated prostate intraepithelial neoplasias and prostatic adenocarcinoma

54 expression of Bmi1 in mice induced prostatic intraepithelial neoplasia, and elicited invasive adenoca

55 eads to the formation of kidney cysts, renal intraepithelial neoplasia, and invasive papillary renal

56 decreased formation of high-grade pancreatic intraepithelial neoplasias, and accelerated development

57 y analyzed for formation of IPMN, pancreatic intraepithelial neoplasias, and PDAC, in addition to pro

58 Transgenic ETV1 mice developed prostatic intraepithelial neoplasia as well as hyperplasia/neoplas

59 n; the corresponding efficacies against anal intraepithelial neoplasia associated with HPV of any typ

60 quadrivalent HPV vaccine (qHPV) against anal intraepithelial neoplasia associated with HPV-6, 11, 16,

61 Efficacy of the qHPV vaccine against anal intraepithelial neoplasia associated with HPV-6, 11, 16,

62 1 induced histological features of prostatic intraepithelial neoplasia at 7 months of age; these feat

63 ce exhibited metaplasia-associated prostatic intraepithelial neoplasia at a low frequency.

64 10 v 2.5 to 3.9 ng/mL), high-grade prostatic intraepithelial neoplasia/atypical glands (HR = 2.97), g

65 sulted in development of high-grade cervical intraepithelial neoplasia, but not frank cervical carcin

66 ally accelerated the progression of prostate intraepithelial neoplasia, by promoting cell proliferati

67 t epithelial atypia (controls); conjunctival intraepithelial neoplasia, carcinoma in situ (CIS); and

68 unlike normal prostate epithelium, prostatic intraepithelial neoplasia cells showed strong coexpressi

69 nterval [CI], 5.1% to 28.7%) and of cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in

70 the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in

71 bout test performance for detecting cervical intraepithelial neoplasia (CIN) and cancer and screening

72 tly diagnosed with higher grades of cervical intraepithelial neoplasia (CIN) and cancer, as compared

73 t the long-term yield of high-grade cervical intraepithelial neoplasia (CIN) and the influence on bio

74 re defined as women classified with cervical intraepithelial neoplasia (CIN) grade 2+ (CIN2+) (n = 10

75 istory and histologically confirmed cervical intraepithelial neoplasia (CIN) in 2.5 years after the b

76 enic human papillomaviruses (HPVs), cervical intraepithelial neoplasia (CIN) is common, and current t

77 ous intraepithelial lesion (SIL) or cervical intraepithelial neoplasia (CIN) prevalence, incidence, p

78 To determine the population-based cervical intraepithelial neoplasia (CIN) trends when adjusting fo

79 Comparison of conjunctival intraepithelial neoplasia (CIN) vs SCC revealed SCC with

80 specimens, including 38 normal, 52 cervical intraepithelial neoplasia (CIN), and 68 cervical cancer

81 or the identification of high-grade cervical intraepithelial neoplasia (CIN).

82 e followed semiannually for HPV and cervical intraepithelial neoplasia (CIN).

83 types in a broader group that cause cervical intraepithelial neoplasia (CIN).

84 ogy for the detection of high-grade cervical intraepithelial neoplasia (CIN).

85 iruses (HPV) results in precancers [cervical intraepithelial neoplasia (CIN)] and cancers near the ec

86 ly increased with disease severity (cervical intraepithelial neoplasia [CIN] 3, 17.9% [+/-7.2] vs CIN

87 ated STAT3 increased from low-grade cervical intraepithelial neoplasia (CIN1) to precancerous CIN3 le

88 nning normalcy, increasingly severe cervical intraepithelial neoplasia (CIN1- CIN3), and cervical can

89 HC2 for the detection of high-grade cervical intraepithelial neoplasia (CIN2+) in a total of 8,610 ce

90 span of progression from high-grade cervical intraepithelial neoplasia (CIN2/3) to invasive cervical

91 r the ability to predict high-grade cervical intraepithelial neoplasias (CIN2 or worse) in correspond

92 cidence rates (CIRs) of >/= grade 3 cervical intraepithelial neoplasia (CIN3+) or cancer for enrollme

93 ied well" patients with high-grade prostatic intraepithelial neoplasia combined with issues of recurr

94 ical surgical prevention includes removal of intraepithelial neoplasia detected by screening (includi

95 established metaplastic lesions, and lost in intraepithelial neoplasia/dysplasia and carcinoma of var

96 anogenital warts, oral warts, and anogenital intraepithelial neoplasias (eg, cervical intraepithelial

97 stologic precursor lesion called endometrial intraepithelial neoplasia (EIN).

98 0beta allele in the prostate drives prostate intraepithelial neoplasia formation.

99 ere dysplasia manifested as gastrointestinal intraepithelial neoplasia (GIN) after 28 weeks post-H. p

100 eous atrophic gastritis and gastrointestinal intraepithelial neoplasia (GIN) with 80% prevalence 6 mo

101 usly expressed in human high-grade prostatic intraepithelial neoplasia, Gleason grades 3 through 5 pr

102 diagnosed cytologically; 1198 with cervical intraepithelial neoplasia grade 1 (CIN1), 456 with CIN2,

103 nst 6-month persistent infection or cervical intraepithelial neoplasia grade 1 or greater (CIN1+) ass

104 d with older age and a diagnosis of cervical intraepithelial neoplasia grade 1 or greater.

105 nst 6-month persistent infection or cervical intraepithelial neoplasia grade 1 or higher (CIN1+) asso

106 h channel based on the detection of cervical intraepithelial neoplasia grade 2 (CIN2) or greater (>/=

107 , clinical performance in detecting cervical intraepithelial neoplasia grade 2 (CIN2) or more severe

108 ic diagnosis of controls (less than cervical intraepithelial neoplasia grade 2 [<CIN2]) or cases (cer

109 t viral load, which varied by type (cervical intraepithelial neoplasia grade 2 [CIN2] for HPV52, CIN3

110 f a high-grade precancerous lesion (cervical intraepithelial neoplasia grade 2 or 3) or cervical canc

111 nce of high-grade cervical disease (cervical intraepithelial neoplasia grade 2 or 3, adenocarcinoma i

112 dy, we selected women with incident cervical intraepithelial neoplasia grade 2 or grade 3 (CIN2/3; n

113 Cumulative risks of cervical intraepithelial neoplasia grade 2 or greater (CIN-2+; th

114 ainst 6-month persistent infection, cervical intraepithelial neoplasia grade 2 or greater (CIN2+) ass

115 the Xpert HPV for the detection of cervical intraepithelial neoplasia grade 2 or higher (CIN2+) and

116 eoplasia grade 2 [<CIN2]) or cases (cervical intraepithelial neoplasia grade 2 or higher [CIN2+]) for

117 des 2/3 and adenocarcinoma in situ (cervical intraepithelial neoplasia grade 2 or higher [CIN2+]) in

118 The sensitivity of Xpert for cervical intraepithelial neoplasia grade 2 or more severe diagnos

119 ing for the detection of underlying cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in th

120 n have used the disease endpoint of cervical intraepithelial neoplasia grade 2 or worse (CIN2+).

121 women with histologically confirmed cervical-intraepithelial neoplasia grade 2 or worse [>or= CIN2])

122 ce in vaccine efficacy (VE) against cervical intraepithelial neoplasia grade 2 or worse in HPV-naive

123 ICIA criteria, VE estimates against cervical intraepithelial neoplasia grade 2 or worse, regardless o

124 nclarity assay for the detection of cervical intraepithelial neoplasia grade 2+ (CIN2+) and CIN3+ was

125 Both assays detected >/=91.7% of cervical intraepithelial neoplasia grade 2+ (CIN2+) lesions.

126 result, we identified 90 women with cervical intraepithelial neoplasia grade 2+ (CIN2+), including 43

127 lastic lesions and invasive cancer (cervical intraepithelial neoplasia grade 2+ [CIN2+]) compared to

128 low specificities for the detection of anal intraepithelial neoplasia grade 2/3 (AIN2/3) in this pop

129 We assessed if risk of developing cervical intraepithelial neoplasia grade 2/3 (CIN2/3) or adenocar

130 uamous intraepithelial lesions (ie, cervical intraepithelial neoplasia grade 2/3 [CIN 2/3]) and (2) i

131 s from patients with HPV-associated cervical intraepithelial neoplasia grade 2/3 and murine skin disp

132 vulvar cancer), and vaginal disease (vaginal intraepithelial neoplasia grade 2/3, vaginal cancer) rel

133 cervical carcinoma), vulvar disease (vulvar intraepithelial neoplasia grade 2/3, vulvar cancer), and

134 specificity (46%-54%) for consensus cervical intraepithelial neoplasia grade 3 (CIN 3).

135 at high risk of cervical cancer or cervical intraepithelial neoplasia grade 3 (CIN3) or worse over 5

136 bstudy was histologically confirmed cervical intraepithelial neoplasia grade 3 (CIN3) or worse.

137 alignancies in women diagnosed with cervical intraepithelial neoplasia grade 3 (CIN3).

138 igibility criteria were biopsy-proven vulval intraepithelial neoplasia grade 3 and at least one lesio

139 aseline specimens from 482 cases of cervical intraepithelial neoplasia grade 3 or cancer (CIN3+) and

140 Similar results were observed for cervical intraepithelial neoplasia grade 3 or higher (CIN3+) (n =

141 The primary endpoint was cervical intraepithelial neoplasia grade 3 or more severe (CIN3+)

142 y outcome was the detection rate of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) in th

143 e timing of diagnosis of histologic cervical intraepithelial neoplasia grade 3 or worse (CIN3+) using

144 stence and/or precancer and cancer [cervical intraepithelial neoplasia grade 3+ (CIN3+)].

145 om women with a diagnosis of CIN3+ (cervical intraepithelial neoplasia grade 3+ or cervical cancer) t

146 ancer, 6.68 (95% CI, 3.64 to 12.25) for anal intraepithelial neoplasia grade 3, 4.97 (95% CI, 3.26 to

147 er, 13.66 (93% CI, 9.69 to 19.25) for vulvar intraepithelial neoplasia grade 3, 86.08 (95% CI, 11.98

148 , 25.65 (95% CI, 10.50 to 62.69) for vaginal intraepithelial neoplasia grade 3, and 5.51 (95% CI, 1.2

149 was upregulated in patients with pancreatic intraepithelial neoplasias grade 3 and PDAC lesions rela

150 sts for hrHPV and HPV 16/18 to find cervical intraepithelial neoplasia (grade >/=2 [CIN2+] or grade >

151 sts for hrHPV and HPV 16/18 to find cervical intraepithelial neoplasia (grade >/=2 [CIN2+] or grade >

152 , anal cancer is preceded by high-grade anal intraepithelial neoplasia (grade 2 or 3).

153 gnificance or greater (ASCUS+), and cervical intraepithelial neoplasia grades 1/2 or greater (CIN1+,

154 1 (HPV31) DNA loads and the risk of cervical intraepithelial neoplasia grades 2 and 3 (CIN2-3) was ev

155 % CI = 37.9 to 68.3) for diagnosing cervical intraepithelial neoplasia grades 2/3 (CIN2/3) on histolo

156 implemented mandatory reporting of cervical intraepithelial neoplasia grades 2/3 and adenocarcinoma

157 Methods used to diagnose and treat cervical intraepithelial neoplasia have important potential adver

158 We modeled fractions of high-grade anal intraepithelial neoplasia (HGAIN) attributable to indivi

159 precancerous anal lesions or high-grade anal intraepithelial neoplasia (HGAIN) have been vaccinated e

160 (MSM) who have a history of high-grade anal intraepithelial neoplasia (HGAIN) was associated with a

161 High-grade prostatic intraepithelial neoplasia (HGPIN) is considered a precur

162 among men with isolated high-grade prostatic intraepithelial neoplasia (HGPIN) on biopsy.

163 tion and progression of high-grade prostatic intraepithelial neoplasia (HGPIN) to prostatic adenocarc

164 e, Pten deletion induces high-grade prostate intraepithelial neoplasia (HGPIN).

165 uman prostate cancer and high-grade prostate intraepithelial neoplasia (HGPIN).

166 e Etk/BMX in mouse prostate induces prostate intraepithelial neoplasia, implying a possible causal ro

167 Confocal laser endomicroscopy can localize intraepithelial neoplasia in chronic ulcerative colitis

168 D2A resulted in the development of prostatic intraepithelial neoplasia in mice, demonstrating that JM

169 g a significant increase in the frequency of intraepithelial neoplasia in patients who received a lip

170 ntly accelerates the initiation of prostatic intraepithelial neoplasia in this model.

171 f the qHPV vaccine reduced the rates of anal intraepithelial neoplasia, including of grade 2 or 3, am

172 cally attenuates the formation of pancreatic intraepithelial neoplasia induced by mutant Kras(G12D),

173 normal prostate glands, high-grade prostatic intraepithelial neoplasia, invasive adenocarcinoma, or p

174 Prostatic intraepithelial neoplasia is a precursor to prostate can

175 Vulval intraepithelial neoplasia is a skin disorder affecting t

176 standard treatment for patients with vulval intraepithelial neoplasia is surgery, but this approach

177 was decoded from five grade 2 or 3 cervical intraepithelial neoplasia lesion (CIN2/3) samples and fi

178 ic introduction of an oncogene for prostatic intraepithelial neoplasia lesion development.

179 PI3K activation occurred early in prostate intraepithelial neoplasia lesion formation in these anim

180 Prostate intraepithelial neoplasia lesions develop in mice with P

181 ramatic hyperplasia and multifocal prostatic intraepithelial neoplasia lesions from adjacent naive ep

182 eficient mice exhibited widespread prostatic intraepithelial neoplasia lesions in all prostatic lobes

183 ce and the replicative activity of prostatic intraepithelial neoplasia lesions in the dorsal prostate

184 Cervical intraepithelial neoplasia lesions of grade two and highe

185 l metaplasia (ADM)-a precursor of pancreatic intraepithelial neoplasia lesions that can progress to P

186 rostate (TRAMP-FVB) mice harboring prostatic intraepithelial neoplasia lesions until 20 weeks of age

187 induction of NFATc2 in late-stage pancreatic intraepithelial neoplasia lesions with increased express

188 cumulate low-grade, pre-malignant pancreatic intraepithelial neoplasia lesions, but progression to hi

189 with development of premalignant pancreatic intraepithelial neoplasia lesions.

190 a and the subsequent formation of pancreatic intraepithelial neoplasia lesions.

191 than reduced, number of low-grade pancreatic intraepithelial neoplasia (mPanIN) lesions.

192 uctal metaplasia (ADM), malignant pancreatic intraepithelial neoplasia (mPanIN), and PDAC within a ye

193 is coexpressed with MUC1 in mouse pancreatic intraepithelial neoplasia (mPanIN)-like lesions and in t

194 Ras activity and in sparse murine pancreatic intraepithelial neoplasias (mPanINs) that did not sponta

195 c-MYC-initiated cells progress to prostatic intraepithelial neoplasia (mPIN) and adenocarcinoma lesi

196 l transgenic mice developed murine prostatic intraepithelial neoplasia (mPIN) and prostatic adenocarc

197 but Tsc1-deficient mice developed prostatic intraepithelial neoplasia (mPIN) in lateral and anterior

198 le transgenic mice displayed mouse prostatic intraepithelial neoplasia (mPIN) in the ventral and dors

199 tive stroma activation surrounding prostatic intraepithelial neoplasia (mPIN) lesions found both in i

200 he transgenic mice displayed mouse prostatic intraepithelial neoplasia (mPIN) lesions.

201 atenin signaling resulted in mouse prostatic intraepithelial neoplasia (mPIN).

202 ) in mice harboring oncogene-driven prostate intraepithelial neoplasia (mPIN).

203 psy-proved squamous cell carcinoma or vulvar intraepithelial neoplasia occurred during follow-up in 0

204 of residual or recurrent high-grade cervical intraepithelial neoplasia of grade two or worse (CIN2+)

205 Men with high-grade anal intraepithelial neoplasia or anal cancer by history or b

206 ry efficacy objective was prevention of anal intraepithelial neoplasia or anal cancer related to infe

207 s and 86.1% in women with NLIM (negative for intraepithelial neoplasia or malignancy) cytology who we

208 evels are associated with a history of prior intraepithelial neoplasia or pT1mic/pT1a breast cancer a

209 High-grade anal intraepithelial neoplasia or worse (HG-AIN+) was diagnos

210 at either noninvasive precursor (pancreatic intraepithelial neoplasia) or the PDAC stage led to inva

211 e than those in therapy-naive PCa, prostatic intraepithelial neoplasia, or benign tissues.

212 ificantly with the progression of pancreatic intraepithelial neoplasias (P = 0.001) and development o

213 0.0001) and dysplasia (increased pancreatic intraepithelial neoplasia, P < 0.01).

214 stem (CNS) occurs as early as the pancreatic intraepithelial neoplasia (PanIN) 2 stage.

215 ), and KC(iMist1) mouse models of pancreatic intraepithelial neoplasia (PanIN) and analyzed by confoc

216 hat underwent ADM can progress to pancreatic intraepithelial neoplasia (PanIN) and eventually pancrea

217 is overexpressed in premalignant pancreatic intraepithelial neoplasia (PanIN) and in the majority of

218 A) develops predominantly through pancreatic intraepithelial neoplasia (PanIN) and intraductal papill

219 d might be viewed as a prelude to pancreatic intraepithelial neoplasia (PanIN) and pancreatic ductal

220 velopment and is induced in mouse pancreatic intraepithelial neoplasia (PanIN) and pancreatic ductal

221 Pancreatic intraepithelial neoplasia (PanIN) are pancreatic cancer

222 ce of oncogenic KRAS, accelerates pancreatic intraepithelial neoplasia (PanIN) formation and the deve

223 ates acinar-to-ductal metaplasia, pancreatic intraepithelial neoplasia (PanIN) formation, and PanIN p

224 We previously demonstrated that pancreatic intraepithelial neoplasia (PanIN) formation, which prece

225 Increasing grade of pancreatic intraepithelial neoplasia (PanIN) has been associated wi

226 progressively develop high-grade pancreatic intraepithelial neoplasia (PanIN) lesions and neoplasia

227 both pancreatic cancer cells and pancreatic intraepithelial neoplasia (PanIN) lesions in human pancr

228 transition from early to advanced pancreatic intraepithelial neoplasia (PanIN) lesions, we assessed w

229 to-ductal metaplasia and in early pancreatic intraepithelial neoplasia (PanIN) lesions.

230 ions then convert to precancerous pancreatic intraepithelial neoplasia (PanIN) that progresses to PDA

231 IS biomarkers in human and murine pancreatic intraepithelial neoplasia (PanIN), and found that only s

232 ed and analyzed for inflammation, pancreatic intraepithelial neoplasia (PanIN), and PDAC.

233 d kinase, inflammation, fibrosis, pancreatic intraepithelial neoplasia (PanIN), and PDACs.

234 C and its preinvasive precursors, pancreatic intraepithelial neoplasia (PanIN), arise via reprogrammi

235 ithelium accelerated formation of pancreatic intraepithelial neoplasia (PanIN), increased the frequen

236 ys, methylation analysis of early pancreatic intraepithelial neoplasia (PanIN), mouse models for PDAC

237 scin deficiency on development of pancreatic intraepithelial neoplasia (PanIn), PDAC, and metastasis.

238 n is expressed in human and mouse pancreatic intraepithelial neoplasia (PanIN), suggesting that N-cad

239 creatic acinar cells give rise to pancreatic intraepithelial neoplasia (PanIN), the most common precu

240 of PDA and its precursor lesion, pancreatic intraepithelial neoplasia (PanIN), we examined the effec

241 Using a murine model of pancreatic intraepithelial neoplasia (PanIN), we found that Kras(G1

242 , thus resisting the formation of pancreatic intraepithelial neoplasia (PanIN)-derived PDA.

243 ing initiation and development of pancreatic intraepithelial neoplasia (PanIN).

244 ise from precursor lesions termed pancreatic intraepithelial neoplasia (PanIN).

245 been hypothesized to give rise to pancreatic intraepithelial neoplasia (PanIN).

246 ancies, including human PDACs and pancreatic intraepithelial neoplasia (PanIN).

247 ar-to-ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN).

248 ate from duct-like lesions called pancreatic intraepithelial neoplasia (PanIN).

249 the formation and maintenance of pancreatic intraepithelial neoplasia (PanINs) in p48Cre; TetO-KrasG

250 iation and expansion of low-grade pancreatic intraepithelial neoplasia (PanINs), likely through diffe

251 titute hallmark features of human pancreatic intraepithelial neoplasia (PanINs), the precursor to pan

252 sufficient to induce formation of pancreatic intraepithelial neoplasia (PanINs)-a precursor of PDAC.

253 tubular complexes (TC) and early pancreatic intraepithelial neoplasia (PanINs).

254 s the development of premalignant pancreatic intraepithelial neoplasias (PanINs) and cystic lesions i

255 ancreatic ductal adenocarcinomas, pancreatic intraepithelial neoplasias (PanINs) and normal pancreas

256 cinar-to-ductal metaplasia (ADM), pancreatic intraepithelial neoplasias (PanINs) and ultimately pancr

257 protected from the development of pancreatic intraepithelial neoplasias (PanINs).

258 EGLs) in men, including condyloma and penile intraepithelial neoplasia (PeIN).

259 Rates of anal intraepithelial neoplasia per 100 person-years were 17.5

260 infection is sufficient to enhance prostate intraepithelial neoplasia (PIN) and microinvasive carcin

261 the Sirt1 gene in mice resulted in prostatic intraepithelial neoplasia (PIN) associated with reduced

262 ostate cancer model, as well as in prostatic intraepithelial neoplasia (PIN) before histological or a

263 s in wild-type mice rarely induced prostatic intraepithelial neoplasia (PIN) in dorsal prostates (one

264 used tumors in multiple organs and prostatic intraepithelial neoplasia (PIN) in mice.

265 ed with development of premalignant prostate intraepithelial neoplasia (PIN) lesions and invasive ade

266 ighly expressed in prostatic hyperplasia and intraepithelial neoplasia (PIN) lesions that also lack N

267 f epithelial hyperplasia and focal prostatic intraepithelial neoplasia (PIN) lesions, but not progres

268 Further, prostatic intraepithelial neoplasia (PIN) progressed to carcinoma

269 d loss of Akap12 and Rb results in prostatic intraepithelial neoplasia (PIN) that fails to progress t

270 sed the prevalence and severity of prostatic intraepithelial neoplasia (PIN), a premalignant lesion.

271 sses: epithelium, stroma, atrophy, prostatic intraepithelial neoplasia (PIN), and prostate cancer Gle

272 rostate cancers, is less common in prostatic intraepithelial neoplasia (PIN), raising questions about

273 (AR) is essential for initiation of prostate intraepithelial neoplasia (PIN), the response of AR-null

274 s ductal hyperplasia and low-grade prostatic intraepithelial neoplasia (PIN).

275 controls, and eventually developed prostatic intraepithelial neoplasia (PIN).

276 en of early-stage prostate cancer [prostatic intraepithelial neoplasia (PIN)] and well-differentiated

277 enign prostatic hyperplasia [BPH], prostatic intraepithelial neoplasia [PIN], inflammation, and atrop

278 SL-KrasG12D model by exacerbating pancreatic intraepithelial neoplasias, promoting facial papillomas,

279 The rate of grade 2 or 3 anal intraepithelial neoplasia related to infection with HPV-

280 nactivation of this GTPase at the pancreatic intraepithelial neoplasia stage promotes pancreatic tiss

281 that survivin interference at the prostatic intraepithelial neoplasia stages may be a potential ther

282 reater number and higher grade of pancreatic intraepithelial neoplasias than KC mice, and 1 mouse dev

283 ons (eg, epithelial hyperplasias and mammary intraepithelial neoplasias) than D1(-/-) females.

284 human pancreatic cancer cells and pancreatic intraepithelial neoplasia, the early lesion of pancreati

285 nic KRAS in both the formation of pancreatic intraepithelial neoplasias, the most common precursor le

286 state cancer (CaP) progresses from prostatic intraepithelial neoplasia through locally invasive adeno

287 PDAC tissues and in premalignant pancreatic intraepithelial neoplasia tissues isolated from Pdx-1-Cr

288 participates in the progression of prostatic intraepithelial neoplasia to adenocarcinoma, and that su

289 is required for the transition of prostatic intraepithelial neoplasia to frank adenocarcinoma.

290 ry of prostate cancer leading from prostatic intraepithelial neoplasia to invasive carcinoma.

291 HmC) in CAFs, in progression from pancreatic intraepithelial neoplasia to PDAC.

292 ntification and treatment of high-grade anal intraepithelial neoplasia to prevent anal cancer are war

293 is an essential component of the pancreatic intraepithelial neoplasias-to-PDAC route in Kras(G12D)-d

294 to document the efficacy of high-grade anal intraepithelial neoplasia treatment to reduce the incide

295 d cancer is not suspected, usual-type vulvar intraepithelial neoplasia treatment, including medical a

296 n paraffin-embedded VSCC and adjacent vulvar intraepithelial neoplasia (VIN) and VLS specimens, in ca

297 increased dramatically when only pancreatic intraepithelial neoplasia were apparent.

298 syndrome, clonal hematopoiesis, and cervical intraepithelial neoplasia which also serve as models for

299 d acinar-to-ductal metaplasia and pancreatic intraepithelial neoplasias, which rapidly progressed to

300 rly neoplastic lesions (high-grade prostatic intraepithelial neoplasia) with striking nuclear atypia

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。